tetano
Editor, Senior Moderator
Clin Transplant
. 2022 Jan 26;e14600.
doi: 10.1111/ctr.14600. Online ahead of print.
Early humoral immune response to two doses of severe acute respiratory syndrome coronavirus 2 vaccine in a diverse group of solid organ transplant candidates and recipients
Howard J Huang[SUP] 1 [/SUP], Stephanie G Yi[SUP] 2 [/SUP], Constance M Mobley[SUP] 2 [/SUP], Ashish Saharia[SUP] 2 [/SUP], Arvind Bhimaraj[SUP] 3 [/SUP], Linda W Moore[SUP] 2 4 [/SUP], Malgorzata Kloc[SUP] 5 [/SUP], Horacio E Adrogue[SUP] 1 [/SUP], Edward A Graviss[SUP] 2 6 [/SUP], Duc T Nguyen[SUP] 6 [/SUP], Todd N Eagar[SUP] 6 [/SUP], Stephen L Jones[SUP] 4 [/SUP], Victor Ankoma-Sey[SUP] 7 [/SUP], Thomas E MacGillivray[SUP] 8 [/SUP], Richard J Knight[SUP] 1 [/SUP], A Osama Gaber[SUP] 1 [/SUP], R Mark Ghobrial[SUP] 1 [/SUP]
Affiliations
Abstract
Response to two doses of a nucleoside-modified messenger ribonucleic acid (mRNA) vaccine was evaluated in a large solid-organ transplant program. mRNA COVID-19 vaccine was administered to transplant candidates and recipients who met study inclusion criteria. Qualitative anti-SARS-CoV-2 Spike Total Immunoglobulin (Ig) and IgG-specific assays, and a semi-quantitative test for anti-SARS-CoV-2 Spike protein IgG were measured in 241 (17.2%) transplant candidates and 1,163 (82.8%) transplant recipients; 55.2% of whom were non-Hispanic White and 44.8% identified as another race. Transplant recipients were a median (IQR) of 3.2 (1.1, 6.8) years from transplantation. Response differed by transplant status: 96.0% vs 43.2% by the anti-SARS-CoV-2 Total Ig (candidates vs recipients, respectively), 93.5% vs 11.6% by the anti-SARS-CoV-2 IgG assay, and 91.9% vs 30.1% by anti-spike titers after two doses of vaccine. Multivariable analysis revealed candidates had higher likelihood of response vs recipients (odds ratio [OR], 14.6; 95 %CI 2.19, 98.11; p = 0.02). A slightly lower response was demonstrated in older patients (OR 0.96; 95 %CI 0.94, 0.99; p = 0.002), patients taking antimetabolites (OR, 0.21; 95% CI 0.08, 0.51; p = 0.001). Vaccination prior to transplantation should be encouraged. This article is protected by copyright. All rights reserved.
. 2022 Jan 26;e14600.
doi: 10.1111/ctr.14600. Online ahead of print.
Early humoral immune response to two doses of severe acute respiratory syndrome coronavirus 2 vaccine in a diverse group of solid organ transplant candidates and recipients
Howard J Huang[SUP] 1 [/SUP], Stephanie G Yi[SUP] 2 [/SUP], Constance M Mobley[SUP] 2 [/SUP], Ashish Saharia[SUP] 2 [/SUP], Arvind Bhimaraj[SUP] 3 [/SUP], Linda W Moore[SUP] 2 4 [/SUP], Malgorzata Kloc[SUP] 5 [/SUP], Horacio E Adrogue[SUP] 1 [/SUP], Edward A Graviss[SUP] 2 6 [/SUP], Duc T Nguyen[SUP] 6 [/SUP], Todd N Eagar[SUP] 6 [/SUP], Stephen L Jones[SUP] 4 [/SUP], Victor Ankoma-Sey[SUP] 7 [/SUP], Thomas E MacGillivray[SUP] 8 [/SUP], Richard J Knight[SUP] 1 [/SUP], A Osama Gaber[SUP] 1 [/SUP], R Mark Ghobrial[SUP] 1 [/SUP]
Affiliations
- PMID: 35083796
- DOI: 10.1111/ctr.14600
Abstract
Response to two doses of a nucleoside-modified messenger ribonucleic acid (mRNA) vaccine was evaluated in a large solid-organ transplant program. mRNA COVID-19 vaccine was administered to transplant candidates and recipients who met study inclusion criteria. Qualitative anti-SARS-CoV-2 Spike Total Immunoglobulin (Ig) and IgG-specific assays, and a semi-quantitative test for anti-SARS-CoV-2 Spike protein IgG were measured in 241 (17.2%) transplant candidates and 1,163 (82.8%) transplant recipients; 55.2% of whom were non-Hispanic White and 44.8% identified as another race. Transplant recipients were a median (IQR) of 3.2 (1.1, 6.8) years from transplantation. Response differed by transplant status: 96.0% vs 43.2% by the anti-SARS-CoV-2 Total Ig (candidates vs recipients, respectively), 93.5% vs 11.6% by the anti-SARS-CoV-2 IgG assay, and 91.9% vs 30.1% by anti-spike titers after two doses of vaccine. Multivariable analysis revealed candidates had higher likelihood of response vs recipients (odds ratio [OR], 14.6; 95 %CI 2.19, 98.11; p = 0.02). A slightly lower response was demonstrated in older patients (OR 0.96; 95 %CI 0.94, 0.99; p = 0.002), patients taking antimetabolites (OR, 0.21; 95% CI 0.08, 0.51; p = 0.001). Vaccination prior to transplantation should be encouraged. This article is protected by copyright. All rights reserved.